Skip to content

A randomized double-blind placebo-controlled human trial on the effect of Yanggujianpai Liqingtong Granule on lowering blood uric acid

A randomized double-blind placebo-controlled human trial on the effect of Yanggujianpai Liqingtong Granule on lowering blood uric acid

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079993
Enrollment
Unknown
Registered
2024-01-17
Start date
2023-02-08
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemia(Damp-heat syndrome)

Interventions

Sponsors

the 983 Hospital of the PLA Joint Service Support Force
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1, age 18-65 years old. 2. In the normal purine diet and without other comorbidities, serum uric acid level was detected twice on the same day by fasting. In the case of no comorbidities, the uric acid level was 420-540umol/L in males and 360-540 Umol /L in females; In patients with hypertension, abnormal lipid metabolism and obesity, the uric acid level was 420-480umol/L in males and 360-480umol/L in females. 3. According to the self-test table of TCM damp-heat constitution, the conversion score is judged as damp-heat quality, and it is in line with TCM damp-heat syndrome. 4, nearly 2 months did not take uric acid lowering drugs. 5. Voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: 1. secondary hyperuricemia: renal insufficiency, blood diseases (leukemia, etc.), malignant tumors (myeloma, etc.), cirrhosis of the liver and other diseases and drug induced hyperuricemia. 2. Preparation for pregnancy, pregnant and lactating women. 3. allergic to the ingredients of the test product. 4. Patients with gout.

Design outcomes

Primary

MeasureTime frame
Blood uric acid;TCM syndrome score scale;

Countries

China

Contacts

Public ContactMeng Yongxia

the 983 Hospital of the PLA Joint Service Support Force

616222939@qq.com+86 22 8432 3777

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026